This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in North Kansas City, MO, Cerner Corporation (CERN) provides healthcare information technology (HCIT) solutions worldwide. The company offers software and hardware solutions that give healthcare providers secure access to clinical, administrative and financial data in a short time. As of February 2018, its products were in use at more than 27,000 facilities around the world. The company had more than 28,000 employees globally, with over 13,000 in Kansas City, Missouri. More than 28,000 Cerner associates are currently employed in 26 countries worldwide
Cerner (CERN) Set to Improve Patient Experience With New Deal
by Zacks Equity Research
The collaboration with GetWellNetwork is likely to allow Cerner (CERN) in enhancing functionality for clients and patients through third-party solutions.
Here's Why You Should Hold Onto Cerner (CERN) Stock for Now
by Zacks Equity Research
Cerner (CERN) keeps its 2019 revenue guidance intact; expects improvement in bookings.
NextGen's (NXGN) Population Health Picked by Ohio-Based UH
by Zacks Equity Research
NextGen's (NXGN) EHR services are expected to enhance patient outcomes at UH.
Varian's AI-Driven Ethos Solution to Boost Global Cancer Care
by Zacks Equity Research
Varian (VAR) expects the Ethos launch to boost its Oncology Systems segment.
Cybersecurity a Top Priority for Healthcare: 3 Stocks to Watch
by Sreyoshi Mukherjee
As cybersecurity is the need of the hour for U.S. healthcare companies, let's keep an eye on three stocks.
SYNH or CERN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SYNH vs. CERN: Which Stock Is the Better Value Option?
Bright Near-Term Outlook for Medical Info Systems Industry
by Sreyoshi Mukherjee
Growth prospects look bright for the Zacks Medical Info Systems industry, thanks to rising need for curtailing medical expenses and AI.
Cerner (CERN) Down 1.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Cerner (CERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OptimizeRx (OPRX) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
OptimizeRx's (OPRX) second-quarter 2019 results are likely to benefit from increased sales of core financial and brand messaging products.
MDRX or CERN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MDRX vs. CERN: Which Stock Is the Better Value Option?
Cerner (CERN) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Cerner (CERN) Q2 results benefit from higher revenues, gains in Licensed software, Professional and Managed services units, and gross margin expansion.
Cerner (CERN) Q2 Earnings Top Estimates
by Zacks Equity Research
Cerner (CERN) delivered earnings and revenue surprises of 3.13% and -0.40%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Offing for Cerner's (CERN) Earnings in Q2?
by Zacks Equity Research
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to aid Cerner's (CERN) Q2 earnings. However, expected decline in bookings is likely to be a dampener.
Here's Why Investors Should Consider Cerner (CERN) Stock
by Zacks Equity Research
For the second quarter, Cerner (CERN) expects revenues between $1.41 billion and $1.46 billion.
Cerner (CERN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cerner (CERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NextGen Inks Deal With Appriss Health, Boosts EHR System
by Zacks Equity Research
NextGen (NXGN) integrates Appriss Health prescription monitoring and tracking analytics into NextGen Office that is likely to enhance the former's EHR system.
Omnicell (OMCL) Catches Eye: Stock Jumps 8.2%
by Zacks Equity Research
Omnicell (OMCL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Tap AI-Powered Medical Device Stocks as FDA Bolsters SaMD
by Urmimala Biswas
The whole MedTech community finds a reason to cheer over with the FDA's recent proposal for Software as a Medical Device.
MDRX vs. CERN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MDRX vs. CERN: Which Stock Is the Better Value Option?
Walgreens Boots (WBA) Q3 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Walgreens Boots' (WBA) Retail Pharmacy USA division gains traction from comparable prescription volume growth and a sturdy retail prescription market.
Boston Scientific Strong on Growth Goals and Future Launches
by Zacks Equity Research
This long-range strategy will aid Boston Scientific (BSX) to deliver a solid financial footing across its MedSurg, Rhythm and Neuro plus Cardiovascular segments.
Teleflex (TFX) Shares Down on Respiratory Care Product Recall
by Zacks Equity Research
Teleflex (TFX) issued a statement saying consumers who own the tampered product should immediately discontinue use and return all affected products.
Bruker (BRKR) Hits a 52-Week High on Solid Growth Drivers
by Zacks Equity Research
Bruker (BRKR) gains from several crucial product launches and acquisitions.
Hill-Rom (HRC) Gains on Product Launch, Prudent Buyouts
by Zacks Equity Research
The contribution from new products is substantial to bolster top-line growth during the first half of fiscal 2019 at Hill-Rom (HRC).
Here's Why You Should Hold GNC Holdings (GNC) Stock for Now
by Zacks Equity Research
GNC Holdings (GNC) continues to witness investors' confidence, courtesy of a few positive factors like strategic new partnerships.